Sale!

COL6A3 Gene Bethlem Myopathy Type 1 Genetic Test

Original price was: $700.Current price is: $500.

-29%

The COL6A3 Gene Bethlem Myopathy Type 1 NGS Genetic DNA Test is a cutting-edge diagnostic tool that identifies mutations in the COL6A3 gene responsible for Bethlem myopathy type 1, a rare form of congenital muscular dystrophy. Using next-generation sequencing technology, this test provides comprehensive analysis of the collagen VI alpha-3 chain gene to detect pathogenic variants that cause progressive muscle weakness and joint contractures. The test is essential for individuals experiencing unexplained muscle weakness, delayed motor milestones, or family history of muscular disorders. Results help guide treatment decisions, inform genetic counseling, and enable early intervention strategies. Available for only $500 USD, this test offers crucial insights into inherited neuromuscular conditions and facilitates personalized medical management approaches for affected individuals and their families.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

COL6A3 Gene Bethlem Myopathy Type 1 NGS Genetic DNA Test

Comprehensive Genetic Testing for Neuromuscular Disorders

The COL6A3 Gene Bethlem Myopathy Type 1 NGS Genetic DNA Test represents a breakthrough in molecular diagnostics for inherited muscular disorders. This advanced genetic analysis specifically targets the COL6A3 gene, which encodes the alpha-3 chain of collagen type VI—a critical component of the extracellular matrix in muscle tissue. When mutations occur in this gene, they disrupt the structural integrity of muscle fibers, leading to the characteristic symptoms of Bethlem myopathy type 1.

What Does This Test Measure?

Our state-of-the-art NGS (Next-Generation Sequencing) technology provides comprehensive analysis of the COL6A3 gene to identify:

  • Pathogenic variants and mutations in the COL6A3 gene
  • Single nucleotide polymorphisms (SNPs) associated with Bethlem myopathy
  • Deletions, insertions, and duplications affecting gene function
  • Variants that disrupt collagen VI assembly and function
  • Inheritance patterns for family genetic counseling

Who Should Consider This Test?

This genetic test is recommended for individuals experiencing:

  • Progressive muscle weakness beginning in childhood or early adulthood
  • Joint contractures affecting fingers, elbows, and ankles
  • Delayed motor milestones in infancy or childhood
  • Family history of muscular dystrophy or neuromuscular disorders
  • Unexplained muscle stiffness or reduced mobility
  • Diagnostic uncertainty regarding muscular weakness etiology

Clinical Indications and Symptoms

Bethlem myopathy type 1 typically presents with characteristic symptoms including:

  • Proximal muscle weakness affecting shoulders and hips
  • Flexion contractures in fingers, wrists, and elbows
  • Hyperextensibility of distal joints
  • Slowly progressive course with variable severity
  • Skin abnormalities including keloid formation
  • Respiratory complications in severe cases

Benefits of COL6A3 Genetic Testing

Undergoing this comprehensive genetic analysis provides numerous advantages:

  • Accurate Diagnosis: Confirms or rules out Bethlem myopathy type 1 with high precision
  • Personalized Treatment: Enables targeted management strategies based on genetic findings
  • Family Planning: Provides crucial information for genetic counseling and reproductive decisions
  • Early Intervention: Facilitates proactive management to slow disease progression
  • Differential Diagnosis: Helps distinguish from other muscular dystrophies with similar presentations
  • Research Contribution: Advances understanding of collagen VI-related disorders

Understanding Your Test Results

Our comprehensive genetic report includes detailed interpretation of your results:

  • Positive Result: Identifies a pathogenic variant in the COL6A3 gene, confirming Bethlem myopathy type 1 diagnosis
  • Negative Result: No disease-causing variants detected, though clinical correlation remains essential
  • Variant of Uncertain Significance (VUS): Identifies genetic changes with unclear clinical impact requiring further evaluation
  • Carrier Status: Determines if you carry one copy of a mutated gene without showing symptoms

Test Details and Pricing

Test Component Details
Test Name COL6A3 Gene Bethlem Myopathy Type 1 NGS Genetic DNA Test
Discount Price $500 USD
Regular Price $700 USD
Turnaround Time 3 to 4 Weeks
Sample Type Blood, Extracted DNA, or One Drop Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS) Technology

Pre-Test Requirements

To ensure optimal testing outcomes, we recommend:

  • Complete clinical history of the patient
  • Genetic counseling session to create detailed family pedigree
  • Documentation of symptoms and disease progression
  • Previous diagnostic test results for comprehensive assessment

Nationwide Testing Availability

We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our network of certified genetic testing facilities ensures consistent, high-quality results regardless of your location.

Take Control of Your Neurological Health Today

Don’t let uncertainty about muscular weakness or family history of neuromuscular disorders delay your diagnosis. Our COL6A3 genetic testing provides the clarity you need to make informed healthcare decisions and access appropriate treatments.

Ready to schedule your test? Contact our genetic specialists today at +1(267) 388-9828 or book your appointment online. Our team is available to answer your questions and guide you through the testing process with compassion and expertise.

Take the first step toward understanding your genetic health and securing your family’s future. With our discounted price of only $500 USD, comprehensive genetic testing for Bethlem myopathy type 1 has never been more accessible.